[2] The head-to-head ACHIEVE-3 trial, published in The Lancet in February 2026, compared orforglipron 36 mg to oral semaglutide 14 mg in 1,698 patients with type 2 diabetes over 52 weeks
The regulatory landscape for compounded GLP-1 programs has shifted meaningfully since early 2025, and anyone committing to a multi-month program deserves a plain-English summary of exactly where things stand
Despite its name, this condition affects far more than tennis players
The bioactive compounds modulate cell activity through selective actions on the intracellular signaling pathways of various components, particularly cytokines and proinflammatory proteins, which play important cellular functions (Miguel et al., 2014)
An injectable blend formulated to support hydration and recovery
In addition to cell bodies, immunohistochemistry also detected GLP-1R-immunoreactivity in dendrites and axons